Skip to main content
Top
Published in: AIDS Research and Therapy 1/2022

Open Access 01-12-2022 | Human Immunodeficiency Virus | Research

Comparison of efavirenz levels in blood and hair with pharmacy refills as measures of adherence and predictors of viral suppression among people living with HIV in Nigeria

Authors: Jacinta N. Nwogu, Samuel O. Ngene, Chinedum P. Babalola, Adeniyi Olagunju, Andrew Owen, Saye H. Khoo, Olayinka A. Kotila, Baiba Berzins, Hideaki Okochi, Regina Tallerico, Monica Gandhi, Babafemi Taiwo

Published in: AIDS Research and Therapy | Issue 1/2022

Login to get access

Abstract

Background

Strategies to support adherence are constrained by the lack of tools to objectively monitor medication intake in low-resource settings. Pharmacologic measures are objective, but pharmacy refill data is more accessible and cost-efficient. This study compared short-term and long-term efavirenz (EFV) drug levels with pharmacy refill adherence data (PRA) and evaluated their ability to predict viral suppression among people living with HIV in Nigeria.

Methods

Paired hair and dried blood spot (DBS) samples were obtained from 91 adults living with HIV receiving 600 mg EFV-based antiretroviral therapy (ART) and EFV concentrations were measured via validated methods using liquid-chromatography-mass-spectrometry. PRA was estimated from pharmacy records, based on the number of days a patient collected medication before or after the scheduled pick-up date. PRA was categorized into ≤ 74%, 75–94% and ≥ 95%, defined as poor, medium and high adherence, respectively. HIV viral loads closest to the hair sampling time (within 6 months) were also abstracted. Receiver Operating Characteristics (ROC) curve analyses compared the ability of adherence metrics to predict viral suppression.

Results

Based on PRA, 81% of participants had high adherence while 11% and 8% had medium and poor adherence, respectively. The median (IQR) EFV concentrations were 6.85 ng/mg (4.56–10.93) for hair and 1495.6 ng/ml (1050.7–2365.8) for DBS. Of the three measures of adherence, hair EFV concentration had the highest Area Under Curve (AUC) to predict viral suppression. Correlations between EFV concentrations in DBS and hair with PRA were positive (r = 0.12, P = 0.27 and r = 0.21, P = 0.05, respectively) but not strong.

Conclusions

EFV concentrations in hair were the strongest predictor of viral suppression and only weakly correlated with pharmacy refill adherence data in Nigeria. This study suggests that resource-limited settings may benefit from objective adherence metrics to monitor and support adherence.
Literature
1.
go back to reference Gachara G, Mavhandu LG, Rogawski ET, Manhaeve C, Bessong PO. Evaluating adherence to antiretroviral therapy using pharmacy refill records in a rural treatment site in South Africa. AIDS Res Treat. 2017;2017:5456219.PubMedPubMedCentral Gachara G, Mavhandu LG, Rogawski ET, Manhaeve C, Bessong PO. Evaluating adherence to antiretroviral therapy using pharmacy refill records in a rural treatment site in South Africa. AIDS Res Treat. 2017;2017:5456219.PubMedPubMedCentral
2.
go back to reference Mudhune V, Gvetadze R, Girde S, Ndivo R, Angira F, Zeh C, et al. Correlation of adherence by pill count, self-report, mems and plasma drug levels to treatment response among women receiving ARV therapy for PMTCT in Kenya. AIDS Behav. 2018;22(3):918–28.CrossRef Mudhune V, Gvetadze R, Girde S, Ndivo R, Angira F, Zeh C, et al. Correlation of adherence by pill count, self-report, mems and plasma drug levels to treatment response among women receiving ARV therapy for PMTCT in Kenya. AIDS Behav. 2018;22(3):918–28.CrossRef
3.
go back to reference Oku AO, Owoaje ET, Ige OK, Oyo-Ita A. Prevalence and determinants of adherence to HAART amongst PLHIV in a tertiary health facility in South-South Nigeria. BMC Infect Dis. 2013;13:401.CrossRef Oku AO, Owoaje ET, Ige OK, Oyo-Ita A. Prevalence and determinants of adherence to HAART amongst PLHIV in a tertiary health facility in South-South Nigeria. BMC Infect Dis. 2013;13:401.CrossRef
4.
go back to reference Adewuya AO, Afolabi MO, Ola BA, Ogundele OA, Ajibare AO, Oladipo BF, et al. The effect of psychological distress on medication adherence in persons with HIV infection in Nigeria. Psychosomatics. 2010;51(1):68–73.CrossRef Adewuya AO, Afolabi MO, Ola BA, Ogundele OA, Ajibare AO, Oladipo BF, et al. The effect of psychological distress on medication adherence in persons with HIV infection in Nigeria. Psychosomatics. 2010;51(1):68–73.CrossRef
5.
go back to reference Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372(6):509–18.CrossRef Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372(6):509–18.CrossRef
6.
go back to reference Dai JY, Hendrix CW, Richardson BA, Kelly C, Marzinke M, Chirenje ZM, et al. Pharmacological measures of treatment adherence and risk of HIV infection in the VOICE study. J Infect Dis. 2016;213(3):335–42.CrossRef Dai JY, Hendrix CW, Richardson BA, Kelly C, Marzinke M, Chirenje ZM, et al. Pharmacological measures of treatment adherence and risk of HIV infection in the VOICE study. J Infect Dis. 2016;213(3):335–42.CrossRef
7.
go back to reference Musinguzi N, Castillo-Mancilla J, Morrow M, Byakwaga H, Mawhinney S, Burdo TH, et al. Antiretroviral therapy adherence interruptions are associated with systemic inflammation among Ugandans who achieved viral suppression. J Acquir Immune Defic Syndr. 2019;82(4):386–91.CrossRef Musinguzi N, Castillo-Mancilla J, Morrow M, Byakwaga H, Mawhinney S, Burdo TH, et al. Antiretroviral therapy adherence interruptions are associated with systemic inflammation among Ugandans who achieved viral suppression. J Acquir Immune Defic Syndr. 2019;82(4):386–91.CrossRef
8.
go back to reference Gandhi M, Devi S, Bacchetti P, Chandy S, Heylen E, Phung N, et al. Measuring adherence to antiretroviral therapy via hair concentrations in India. J Acquir Immune Defic Syndr. 2019;81(2):202–6.CrossRef Gandhi M, Devi S, Bacchetti P, Chandy S, Heylen E, Phung N, et al. Measuring adherence to antiretroviral therapy via hair concentrations in India. J Acquir Immune Defic Syndr. 2019;81(2):202–6.CrossRef
9.
go back to reference Alcaide ML, Ramlagan S, Rodriguez VJ, Cook R, Peltzer K, Weiss SM, et al. Self-report and dry blood spot measurement of antiretroviral medications as markers of adherence in pregnant women in rural South Africa. AIDS Behav. 2017;21(7):2135–40.CrossRef Alcaide ML, Ramlagan S, Rodriguez VJ, Cook R, Peltzer K, Weiss SM, et al. Self-report and dry blood spot measurement of antiretroviral medications as markers of adherence in pregnant women in rural South Africa. AIDS Behav. 2017;21(7):2135–40.CrossRef
10.
go back to reference Baxi SM, Liu A, Bacchetti P, Mutua G, Sanders EJ, Kibengo FM, et al. Comparing the novel method of assessing PrEP adherence/exposure using hair samples to other pharmacologic and traditional measures. J Acquir Immune Defic Syndr. 2015;68(1):13–20.CrossRef Baxi SM, Liu A, Bacchetti P, Mutua G, Sanders EJ, Kibengo FM, et al. Comparing the novel method of assessing PrEP adherence/exposure using hair samples to other pharmacologic and traditional measures. J Acquir Immune Defic Syndr. 2015;68(1):13–20.CrossRef
11.
go back to reference Castillo-Mancilla JR, Searls K, Caraway P, Zheng JH, Gardner EM, Predhomme J, et al. Short communication: Tenofovir diphosphate in dried blood spots as an objective measure of adherence in HIV-infected women. AIDS Res Hum Retrovir. 2015;31(4):428–32.CrossRef Castillo-Mancilla JR, Searls K, Caraway P, Zheng JH, Gardner EM, Predhomme J, et al. Short communication: Tenofovir diphosphate in dried blood spots as an objective measure of adherence in HIV-infected women. AIDS Res Hum Retrovir. 2015;31(4):428–32.CrossRef
12.
go back to reference Castillo-Mancilla JR, Haberer JE. Adherence measurements in HIV: new advancements in pharmacologic methods and real-time monitoring. Curr HIV/AIDS Rep. 2018;15(1):49–59.CrossRef Castillo-Mancilla JR, Haberer JE. Adherence measurements in HIV: new advancements in pharmacologic methods and real-time monitoring. Curr HIV/AIDS Rep. 2018;15(1):49–59.CrossRef
13.
go back to reference Kagee A, Nel A. Assessing the association between self-report items for HIV pill adherence and biological measures. AIDS Care. 2012;24(11):1448–52.CrossRef Kagee A, Nel A. Assessing the association between self-report items for HIV pill adherence and biological measures. AIDS Care. 2012;24(11):1448–52.CrossRef
14.
go back to reference Wendel CS, Mohler MJ, Kroesen K, Ampel NM, Gifford AL, Coons SJ. Barriers to use of electronic adherence monitoring in an HIV clinic. Ann Pharmacother. 2001;35(9):1010–5.CrossRef Wendel CS, Mohler MJ, Kroesen K, Ampel NM, Gifford AL, Coons SJ. Barriers to use of electronic adherence monitoring in an HIV clinic. Ann Pharmacother. 2001;35(9):1010–5.CrossRef
15.
go back to reference Podsadecki TJ, Vrijens BC, Tousset EP, Rode RA, Hanna GJ. “White coat compliance” limits the reliability of therapeutic drug monitoring in HIV-1-infected patients. HIV Clin Trials. 2008;9(4):238–46.CrossRef Podsadecki TJ, Vrijens BC, Tousset EP, Rode RA, Hanna GJ. “White coat compliance” limits the reliability of therapeutic drug monitoring in HIV-1-infected patients. HIV Clin Trials. 2008;9(4):238–46.CrossRef
16.
go back to reference Spinelli MA, Haberer JE, Chai PR, Castillo-Mancilla J, Anderson PL, Gandhi M. Approaches to objectively measure antiretroviral medication adherence and drive adherence interventions. Curr HIV/AIDS Rep. 2020;17(4):301–14.CrossRef Spinelli MA, Haberer JE, Chai PR, Castillo-Mancilla J, Anderson PL, Gandhi M. Approaches to objectively measure antiretroviral medication adherence and drive adherence interventions. Curr HIV/AIDS Rep. 2020;17(4):301–14.CrossRef
17.
go back to reference Mekuria LA, Prins JM, Yalew AW, Sprangers MA, Nieuwkerk PT. Sub-optimal adherence to combination anti-retroviral therapy and its associated factors according to self-report, clinician-recorded and pharmacy-refill assessment methods among HIV-infected adults in Addis Ababa. AIDS Care. 2017;4:428–35.CrossRef Mekuria LA, Prins JM, Yalew AW, Sprangers MA, Nieuwkerk PT. Sub-optimal adherence to combination anti-retroviral therapy and its associated factors according to self-report, clinician-recorded and pharmacy-refill assessment methods among HIV-infected adults in Addis Ababa. AIDS Care. 2017;4:428–35.CrossRef
18.
go back to reference Israel G. Determining sample size. Univ Florida Facts Sheet PEOD-6. 1992;6. Israel G. Determining sample size. Univ Florida Facts Sheet PEOD-6. 1992;6.
19.
go back to reference Gandhi M, Ameli N, Bacchetti P, Anastos K, Gange SJ, Minkoff H, et al. Atazanavir concentration in hair is the strongest predictor of outcomes on antiretroviral therapy. Clin Infect Dis. 2011;52(10):1267–75.CrossRef Gandhi M, Ameli N, Bacchetti P, Anastos K, Gange SJ, Minkoff H, et al. Atazanavir concentration in hair is the strongest predictor of outcomes on antiretroviral therapy. Clin Infect Dis. 2011;52(10):1267–75.CrossRef
20.
go back to reference Been SK, Yildiz E, Nieuwkerk PT, Pogány K, Van De Vijver DA, Verbon A. Self-reported adherence and pharmacy refill adherence are both predictive for an undetectable viral load among HIV-infected migrants receiving cART. PLoS ONE. 2017;12(11):e0186912.CrossRef Been SK, Yildiz E, Nieuwkerk PT, Pogány K, Van De Vijver DA, Verbon A. Self-reported adherence and pharmacy refill adherence are both predictive for an undetectable viral load among HIV-infected migrants receiving cART. PLoS ONE. 2017;12(11):e0186912.CrossRef
21.
go back to reference Gandhi M, Greenblatt RM, Bacchetti P, Jin C, Huang Y, Anastos K, et al. A single-nucleotide polymorphism in CYP2B6 leads to >3-fold increases in efavirenz concentrations in plasma and hair among HIV-infected women. J Infect Dis. 2012;206(9):1453–61.CrossRef Gandhi M, Greenblatt RM, Bacchetti P, Jin C, Huang Y, Anastos K, et al. A single-nucleotide polymorphism in CYP2B6 leads to >3-fold increases in efavirenz concentrations in plasma and hair among HIV-infected women. J Infect Dis. 2012;206(9):1453–61.CrossRef
22.
go back to reference Nwogu JN, Gandhi M, Owen A, Khoo S, Taiwo B, Olagunju A, et al. Associations between efavirenz concentrations, pharmacogenetics, and neurocognitive performance in people living with HIV in Nigeria. AIDS. 2021;35(12):1919–27.CrossRef Nwogu JN, Gandhi M, Owen A, Khoo S, Taiwo B, Olagunju A, et al. Associations between efavirenz concentrations, pharmacogenetics, and neurocognitive performance in people living with HIV in Nigeria. AIDS. 2021;35(12):1919–27.CrossRef
23.
go back to reference Huang Y, Gandhi M, Greenblatt RM, Gee W, Lin ET, Messenkoff N. Sensitive analysis of anti-HIV drugs, efavirenz, lopinavir and ritonavir, in human hair by liquid chromatography coupled with tandem mass spectrometry. Rapid Commun Mass Spectrom. 2008;22(21):3401–9.CrossRef Huang Y, Gandhi M, Greenblatt RM, Gee W, Lin ET, Messenkoff N. Sensitive analysis of anti-HIV drugs, efavirenz, lopinavir and ritonavir, in human hair by liquid chromatography coupled with tandem mass spectrometry. Rapid Commun Mass Spectrom. 2008;22(21):3401–9.CrossRef
24.
go back to reference Browne RW, Rosenkranz SL, Wang Y, Taylor CR, DiFrancesco R, Morse GD. Sources of variability and accuracy of performance assessment in the clinical pharmacology quality assurance proficiency testing program for antiretrovirals. Ther Drug Monit. 2019;41(4):452–8.CrossRef Browne RW, Rosenkranz SL, Wang Y, Taylor CR, DiFrancesco R, Morse GD. Sources of variability and accuracy of performance assessment in the clinical pharmacology quality assurance proficiency testing program for antiretrovirals. Ther Drug Monit. 2019;41(4):452–8.CrossRef
25.
go back to reference Amara AB, Else LJ, Tjia J, Olagunju A, Puls RL, Khoo S, et al. A validated method for quantification of efavirenz in dried blood spots using high-performance liquid chromatography-mass spectrometry. Ther Drug Monit. 2015;37(2):220–8.CrossRef Amara AB, Else LJ, Tjia J, Olagunju A, Puls RL, Khoo S, et al. A validated method for quantification of efavirenz in dried blood spots using high-performance liquid chromatography-mass spectrometry. Ther Drug Monit. 2015;37(2):220–8.CrossRef
26.
go back to reference Da W, Li X, Qiao S, Zhou Y, Shen Z. Evaluation of self-report adherence measures and their associations with detectable viral load among people living with HIV (PLHIV) in China. PLoS ONE. 2018;13(8):e0203032.CrossRef Da W, Li X, Qiao S, Zhou Y, Shen Z. Evaluation of self-report adherence measures and their associations with detectable viral load among people living with HIV (PLHIV) in China. PLoS ONE. 2018;13(8):e0203032.CrossRef
27.
go back to reference San Lio MM, Carbini R, Germano P, Guidotti G, Mancinelli S, Magid NA, et al. Evaluating adherence to highly active antiretroviral therapy with use of pill counts and viral load measurement in the drug resources enhancement against AIDS and malnutrition program in Mozambique. Clin Infect Dis. 2008;46(10):1609–16.CrossRef San Lio MM, Carbini R, Germano P, Guidotti G, Mancinelli S, Magid NA, et al. Evaluating adherence to highly active antiretroviral therapy with use of pill counts and viral load measurement in the drug resources enhancement against AIDS and malnutrition program in Mozambique. Clin Infect Dis. 2008;46(10):1609–16.CrossRef
28.
go back to reference Baxi SM, Greenblatt RM, Bacchetti P, Jin C, French AL, Keller MJ, et al. Nevirapine concentration in hair samples is a strong predictor of virologic suppression in a prospective cohort of HIV-infected patients. PLoS ONE. 2015;10(6):e0129100.CrossRef Baxi SM, Greenblatt RM, Bacchetti P, Jin C, French AL, Keller MJ, et al. Nevirapine concentration in hair samples is a strong predictor of virologic suppression in a prospective cohort of HIV-infected patients. PLoS ONE. 2015;10(6):e0129100.CrossRef
29.
go back to reference Koss CA, Natureeba P, Mwesigwa J, Cohan D, Nzarubara B, Bacchetti P, et al. Hair concentrations of antiretrovirals predict viral suppression in HIV-infected pregnant and breastfeeding Ugandan women. AIDS. 2015;29(7):825–30.CrossRef Koss CA, Natureeba P, Mwesigwa J, Cohan D, Nzarubara B, Bacchetti P, et al. Hair concentrations of antiretrovirals predict viral suppression in HIV-infected pregnant and breastfeeding Ugandan women. AIDS. 2015;29(7):825–30.CrossRef
30.
go back to reference Gandhi M, Ameli N, Bacchetti P, Gange SJ, Anastos K, Levine A, et al. Protease inhibitor levels in hair strongly predict virologic response to treatment. AIDS. 2009;23(4):471–8.CrossRef Gandhi M, Ameli N, Bacchetti P, Gange SJ, Anastos K, Levine A, et al. Protease inhibitor levels in hair strongly predict virologic response to treatment. AIDS. 2009;23(4):471–8.CrossRef
31.
go back to reference Yan J, Liu J, Su B, Pan X, Wang Z, Wu J, et al. Lamivudine concentration in hair and prediction of virologic failure and drug resistance among HIV patients receiving free ART in China. PLoS ONE. 2016;11(4):e0154421.CrossRef Yan J, Liu J, Su B, Pan X, Wang Z, Wu J, et al. Lamivudine concentration in hair and prediction of virologic failure and drug resistance among HIV patients receiving free ART in China. PLoS ONE. 2016;11(4):e0154421.CrossRef
32.
go back to reference Tamuzi JL, Bulabula AH, Milambo JP, Tshimwanga JL, Kazadi VT. Antiretroviral concentrations in hair as a tool for monitoring antiretroviral therapy adherence: systematic review and meta-analysis. Int J Innov Res Adv Stud. 2017;4(12):135–141. Tamuzi JL, Bulabula AH, Milambo JP, Tshimwanga JL, Kazadi VT. Antiretroviral concentrations in hair as a tool for monitoring antiretroviral therapy adherence: systematic review and meta-analysis. Int J Innov Res Adv Stud. 2017;4(12):135–141.
33.
go back to reference Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133(1):21–30.CrossRef Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133(1):21–30.CrossRef
34.
go back to reference Kobin AB, Sheth NU. Levels of adherence required for virologic suppression among newer antiretroviral medications. Ann Pharmacother. 2011;45(3):372–9.CrossRef Kobin AB, Sheth NU. Levels of adherence required for virologic suppression among newer antiretroviral medications. Ann Pharmacother. 2011;45(3):372–9.CrossRef
35.
go back to reference Leach OHE, Lu H, Caballero J, Thomas JE, Spencer EC, Cook RL. Defining the optimal cut-point of self-reported ART adherence to achieve viral suppression in the era of contemporary HIV therapy: a cross-sectional study. AIDS Res Ther. 2021;18(1):36.CrossRef Leach OHE, Lu H, Caballero J, Thomas JE, Spencer EC, Cook RL. Defining the optimal cut-point of self-reported ART adherence to achieve viral suppression in the era of contemporary HIV therapy: a cross-sectional study. AIDS Res Ther. 2021;18(1):36.CrossRef
36.
go back to reference Deschamps AE, Van Wijngaerden E, Denhaerynck K, De Geest S, Vandamme AM. Use of electronic monitoring induces a 40-day intervention effect in HIV patients. J Acquir Immune Defic Syndr. 2006;43(2):247–8.CrossRef Deschamps AE, Van Wijngaerden E, Denhaerynck K, De Geest S, Vandamme AM. Use of electronic monitoring induces a 40-day intervention effect in HIV patients. J Acquir Immune Defic Syndr. 2006;43(2):247–8.CrossRef
37.
go back to reference Nwogu JN, Babalola CP, Ngene SO, Taiwo BO, Berzins B, Gandhi M. Willingness to donate hair samples for research among people living with HIV/AIDS attending a tertiary health facility in Ibadan. Niger AIDS Res Hum Retrovir. 2019;35(7):642–8.CrossRef Nwogu JN, Babalola CP, Ngene SO, Taiwo BO, Berzins B, Gandhi M. Willingness to donate hair samples for research among people living with HIV/AIDS attending a tertiary health facility in Ibadan. Niger AIDS Res Hum Retrovir. 2019;35(7):642–8.CrossRef
38.
go back to reference Herbertson EC, Lahiri CD, Nwogu JN, Soremekun RO, Olugbake OA, Ezechi OC, et al. High acceptability of donating hair and other biological samples for research among people living with HIV in an outpatient clinic in Lagos. Niger AIDS Res Hum Retrovir. 2021;37(9):676–82.CrossRef Herbertson EC, Lahiri CD, Nwogu JN, Soremekun RO, Olugbake OA, Ezechi OC, et al. High acceptability of donating hair and other biological samples for research among people living with HIV in an outpatient clinic in Lagos. Niger AIDS Res Hum Retrovir. 2021;37(9):676–82.CrossRef
Metadata
Title
Comparison of efavirenz levels in blood and hair with pharmacy refills as measures of adherence and predictors of viral suppression among people living with HIV in Nigeria
Authors
Jacinta N. Nwogu
Samuel O. Ngene
Chinedum P. Babalola
Adeniyi Olagunju
Andrew Owen
Saye H. Khoo
Olayinka A. Kotila
Baiba Berzins
Hideaki Okochi
Regina Tallerico
Monica Gandhi
Babafemi Taiwo
Publication date
01-12-2022
Publisher
BioMed Central
Published in
AIDS Research and Therapy / Issue 1/2022
Electronic ISSN: 1742-6405
DOI
https://doi.org/10.1186/s12981-022-00462-3

Other articles of this Issue 1/2022

AIDS Research and Therapy 1/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine